Search

everythinglearnresearchcommunity

for

Search:↓

Men with benign prostatic hyperplasia are more likely to have metabolic syndrome than those without it.

5-alpha-reductase inhibitors help treat urinary symptoms from an enlarged prostate.

The review suggests there's no agreed treatment for Frontal Fibrosing Alopecia, but hydroxychloroquine and 5a-reductase inhibitors are most effective. New treatments like platelet-rich plasma and LED light could help if standard treatments fail.

Some treatments can stabilize Frontal Fibrosing Alopecia, but more research is needed to find effective treatments, and hair transplants often fail.

Some common medications can harm male fertility, but many effects can be reversed.

Combination therapies work better than single treatments for hair loss.

Dutasteride is linked to a higher chance of sexual dysfunction, especially in younger males and the elderly.

Consider benefits and risks of new alopecia treatments for safety.

Finasteride reduces the need for prostate surgery but may increase the risk of depression and persistent sexual side effects.

Long-term medication for enlarged prostate might not clearly affect the timing or outcomes of later surgery.

5-alpha reductase inhibitors may reduce bladder cancer recurrence and improve survival.

Finasteride may help treat female hair loss, but has risks.

Tamsulosin may slightly increase dementia risk compared to other treatments for enlarged prostate.

5-alpha-reductase inhibitors significantly affect the penile tissue of hypertensive rats.

5α-reductase inhibitors can interfere with doping tests by masking banned substances.

SRD5A2 methylation in blood can predict how well someone will respond to finasteride treatment.

The research found that compound 6, a newly created steroid, is more effective at inhibiting 5α-reductase (an enzyme) than current treatments, suggesting it could be a better option for treating urinary tract symptoms in men.

Using 5-alpha-reductase inhibitors may improve bladder cancer survival in men.

Certain medications, especially 5-α reductase inhibitors and neuropsychiatric drugs, are often linked to erectile dysfunction.

The document suggests that drugs for prostate issues might cause lasting sexual, mental, and physical health problems due to blood vessel damage in the penis.

COVID-19 might worsen symptoms and progression of benign prostatic hyperplasia, possibly due to inflammation and metabolic disturbances in the prostate gland. More research is needed to confirm this.

Some drugs may reduce prostatitis symptoms short-term with few side effects.

Dutasteride use can lead to a stable decline in sexual function that is not affected by age or prostate size.

Patients and doctors find current hair loss treatments unsatisfying and believe involving patients in decisions improves results.

5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.

Using hair loss drugs finasteride and dutasteride may cause sexual side effects.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

Men taking 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had a lower risk of dying from the disease.

Frontal fibrosing alopecia causes hairline recession and eyebrow loss in postmenopausal women.

Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.